Table 3.
No impairment or single system impairment versus dual or multisystem impairment in HIV‐infected participants
| None/single system (n = 235) | Dual/multisystem (n = 149) | p‐value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 11.8 (1.6) | 12.2 (1.6) | 0.02 |
| Female | 121 (51.5) | 62 (41.6) | 0.06 |
| History and symptoms | |||
| Wheeze | 21 (8.9) | 22 (14.8) | 0.08 |
| Shortness of breath | 7 (3.0) | 5 (3.4) | 1.00 |
| Cough | 26 (11.1) | 26 (17.8) | 0.07 |
| Repeated a year at school | 109 (46.4) | 110 (73.8) | 0.00 |
| Previous TB | 135 (58.2) | 99 (66.9) | 0.09 |
| Age at ART initiation | |||
| Median age | 4.0 (1.7 to 7.7) | 4.4 (2.1 to 7.0) | 0.60 |
| 0 to 2 | 97 (42.4) | 54 (36.7) | 0.16 |
| 3 to 5 | 50 (21.8) | 45 (30.6) | |
| 6 to 14 | 82 (35.8) | 48 (32.7) | |
| Current ART regimen | |||
| 2 × NRTI + NNRTI | 134 (58.3) | 91 (61.9) | 0.09 |
| 2 × NRTI + PI | 94 (40.9) | 50 (34.0) | |
| Other | 2 (0.9) | 6 (4.1) | |
| Growth measures | |||
| BMI (kg/m2) | 17.2 (16.0 to 19.0) | 16.9 (15.7 to 18.6) | 0.12 |
| Height | 140.3 (10.0) | 141.2 (10.9) | 0.41 |
| Stunted | 54 (23.0) | 47 (31.5) | 0.06 |
| Puberty | |||
| Pre‐pubertal (Tanner stage 1) | 109 (47.4) | 66 (44.9) | 0.64 |
| Pubertal (Tanner stage 2 to 5) | 121 (52.6) | 81 (55.1) | |
| WHO stage | |||
| Stage I | 18 (8.0) | 10 (7.2) | 0.90 |
| Stage II | 25 (11.1) | 13 (9.4) | |
| Stage III | 131 (58.0) | 86 (61.9) | |
| Stage IV | 52 (23.6) | 30 (21.6) | |
| Laboratory measures | |||
| Viral Load (copies/mL) | |||
| <50 | 192 (82.1) | 110 (73.8) | 0.03 |
| 50 to 1000 | 23 (9.8) | 14 (9.4) | |
| >1000 | 19 (8.1) | 25 (16.8) | |
| CD4 count <200 (cells/mm³) | 5 (2.2) | 3 (2.0) | 0.50 |